Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO

...S EST), Level 2, West Hall C. The poster entitled " P h ase I e val u ation of orally-ad m inistered CYT997, a nov e l cytotoxic vascular- d isrupting agent, in patients with advanced cance r " details safety, tolerability and pre...

YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER

...onths, which compares very favorably with historical data (Brundage Can J Oncol. 1996 Feb; 6 Suppl 1:25-32.; Bezjak Int J Radiat Oncol Biol Phys. 2002 nov 1;54(3):719-28; Sundstrom J Clin Oncol. 2004 Mar 1;22(5):801-10). "Numerous NSCLC patients undergo radiotherapy because they are unfit for radical c...

/C O R R E C T I O N -- Rosetta Genomics Ltd/

... In the news release, "Rosetta Genomics to Present at Rodman & Renshaw 10th Annual Healthcare Conference" issued on 5 nov 2008 13:30 GMT, by Rosetta Genomics Ltd nasdaq:ROSG over PR Newswire, we are advised by a representative of the company that new webcast information h...

European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia

...uloxetine 60-120 mg Versus Placebo in the Treatment of Fibromyalgia Syndrome. Poster presented at the American College of Rheumatology Annual Meeting; nov 2007, Boston, MA. (5) Chappell, AS, et al. A 1-Year Safety and Efficacy Study of Duloxetine in Patients with Fibromyalgia. Poster presented at Europ...

Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery

...clinic/ta/gist/gist1.htm 7. Gleevec(R) (imatinib mesylate) tablets prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; nov 2007. Media Contacts Media only: Kim Fox, Novartis Oncology, P: +1 862 778 7692 Dana Kahn Cooper, P: +1 732 817 1800, C: +1 732 239 6664 Inve...

Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia

...udy. Blood, Feb 2008. 3. Gleevec(R) (imatinib mesylate) tablets prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; nov 2007. Media Contacts Media Only: Kim Fox Novartis Oncology P: +1 862 778 7692 C: +1 917 415 2425 Dana Kahn Cooper P: +1 732 817 1800 C: +1...

FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults

..., Education and Welfare, 1976 9. "Introduction," Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder. NIH Consensus Statement 1998 nov 16-18; 16(2): 1-37. Available at: http://consensus.nih.gov/1998/1998AttentionDeficitHyperactivityDisorder11 0html.htm Accessed on May 7, 2007 (...

FDA Accepts Ranexa(R) sNDA and NDA for Filing

... PALO ALTO, Calif., nov 19 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) announced today that the U.S. Food and Drug Administration (FDA) has notified the ...

BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet

...://www.signplus.com/company Contact: Softpro GmbH, Joerg-M. Lenz, jle@softpro.de , Mobile: +49-160-4788-512, at the show in Las Vegas from nov 13 - 15 Wilhelmstrasse 34, 71034 Boeblingen, Germany ...

Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales

...is as follows: 2007 Financial Guidance as of as of as of (dollars in millions) Jan 4, 2007 Jul 26, 2007 nov 1, 2007 VELCADE U.S. net sales $240 - 260 $250 - 260 $~265 Royalties $140 - 150 $150 - 155 $~160 ...

Oragene is compatible with TaqMan SNP genotyping

... Trends Genet. 14, 266272. 3. Technical Bulletin: DNA Quantification Using the Fluorescence/DNase (F/D) Assay, v1.2. DNA Genotek. nov 29, 2004. 4. TaqMan SNP Genotyping Assays Protocol. Part Number 4332856 Rev. B. Applied Biosystems. June, 2004. back...

Oragene and Whole Genome Amplification with GenomiPhi

... Biotech. 21(12): 531-535. 2. Technical Bulletin: DNA Quantification Using the Fluorescence/DNase (F/D) Assay, v1.2. DNA Genotek. nov 29, 2004. 3. TaqMan SNP Genotyping Assays Protocol. Part Number 4332856 Rev. B. Applied Biosystems. June, 2004. 4. Tec...